Share This
Create Your Own Business Intelligence Website
 
Input the stock code or the company name     Search  

<00512.HK> - Grand Pharmaceutical Group Limited

 
 
 Basic Datum
Company name Lot P/E P/B EPS DPS
GRAND PHARMA 500 7.63 1.0187 0.536 0.26
Profile Information Data Financial Ratios Profit Loss Cash Flow Balance Earnings Dividend
 
 
 
 Company Rating
Date Broker Company name Rating Target
≫More
 
 Company performance - Published
Date Company name Turnover* Profit* % Dividend
≫More
 
 Comment
2024-11-05　２０２４年１０月１８日，遠大醫藥集團有限公司(簡稱：遠大醫藥，股票代碼：００５１２．ＨＫ)心腦血管精准介入診療板塊國產首款可調節取栓支架鸕茲ＬＵＣＩ(國械注准：２０２４３０３２０７３)，正式取得國家藥品監督管理局的上市批准。
 
2024-11-19　遠大醫藥公布公告，宣布與ＳＩＲＴＥＸ ＭＥＤＩＣＡＬ簽訂了２０２４分銷協議。依據協議，北京普爾偉業與成都普爾偉業將作為ＳＩＲＴＥＸ ＭＥＤＩＣＡＬ在中國的獨家經銷商，購買固定數量的產品進行轉售。２０２４分銷協議的有效期為自簽署之日起至２０２５年１１月１４日，期間北京普爾偉業將最多購買８００套產品，而成都普爾偉業將最多購買２００套產品。
 
2024-11-26　遠大醫藥在眼科領域已積累了十余年的發展經驗，公司是我國重要的眼科藥研發、生產及銷售綜合企業之一，並於業內率先提出打造集「預防+治療+保健」的「大五官生態圈」理念。產品管線方面，遠大醫藥眼科在售產品管線數量位居行業前列，公司不僅手握療效及商業化表現雙佳的拳頭產品(如國內治療干眼症的一線用藥瑞珠，以及國家中藥保護品種和血明目片等)，還有一系列在研創新產品儲備，產品梯隊建設齊全完備。
 
2024-12-03　截至２０２４年１１月２８日收盤，遠大醫藥報收於４．５５港元，上揚３．４１％，換手率０．１６％，成交量５６９．４萬股，成交額２５６６．６９萬港元。投行對該股的評級以優於大市為主，近９０天內共有１家投行給出優於大市評級。西部證券最新一份研報給予遠大醫藥買進評級。
 
2024-12-03　遠大醫藥公布自願性公告，宣布其全球創新放射性核素偶聯藥物ＴＬＸ２５０-ＣＤＸ在中國ＩＩＩ期臨床研究已完成首例患者入組並給藥。該研究旨在評估ＴＬＸ２５０-ＣＤＸ在無創檢測腎透明細胞癌的安全性、耐受性及有效性，計劃入組８２名患者。這一發展標志著公司在核藥抗腫瘤診療領域的主要研發發展。
 
2024-12-03　遠大醫藥公布公告稱，用於眼科術後抗炎鎮痛的全球創新激素納米混懸滴眼液ＧＰＮ００８３３完成了國內ＩＩＩ期臨床研究並成功達到了臨床終點。
 
 
 Top Gain / Loss Show All Charts 
 
 Value
Name Updated Value Change Change %
HSI 01-13 09:30 18846.2 ▼ 218.14 ▼ 1.14%
GRAND PHARMA 05-08 13:06 4.72 ▲ 4.72 ▲ ∞%
≫More
 
 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.